Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PROVE-IT proved it: lower is better--pro.

Lawrence A Leiter1

  • 1St. Michael's Hospital, University of Toronto, Ontario. leiterl@shm.toronto.on.ca

The Canadian Journal of Cardiology
|February 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.

Journal of the American Heart Association·2026
Same author

Efficacy of phytosterols for reduction of cardiometabolic risk factors: An umbrella review of systematic reviews and meta-analyses and updated dose-response meta-analyses of randomized trials.

Clinical nutrition (Edinburgh, Scotland)·2026
Same author

Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial.

Diabetes care·2026
Same author

Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.

Circulation·2026
Same author

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial.

Circulation·2026
Same author

Effect of Different Types of Whole Dietary Pulses on Established Therapeutic Lipid Targets for Cardiovascular Risk Reduction: An Updated Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.

Journal of the American Heart Association·2026

Lowering low-density lipoprotein cholesterol (LDL-C) significantly reduces cardiovascular events and atherosclerosis progression. Achieving the lowest on-treatment LDL-C levels offers the greatest benefit, particularly for high-risk individuals.

Area of Science:

  • Cardiovascular Medicine
  • Epidemiology
  • Clinical Trials

Background:

  • Lowering low-density lipoprotein cholesterol (LDL-C) is crucial for cardiovascular health.
  • Epidemiological and clinical data consistently link lower LDL-C to reduced cardiovascular events.

Purpose of the Study:

  • To evaluate the relationship between LDL-C reduction and cardiovascular event rates.
  • To assess the impact of LDL-C lowering on atherosclerosis progression.

Main Methods:

  • Analysis of prospective epidemiological studies.
  • Review of randomized controlled trials (RCTs) and angiographic studies.

Main Results:

  • Lower LDL-C concentrations correlate with the greatest reduction in cardiovascular events.

Related Experiment Videos

  • Lowest coronary artery disease mortality observed in individuals with the lowest cholesterol levels.
  • Trials with the lowest on-treatment LDL-C and greatest LDL-C lowering showed least atherosclerosis progression.

    • Conclusions:

    • Lowering LDL-C is directly proportional to reduced risk of first and subsequent coronary events.
    • An aggressive LDL-C lowering strategy is warranted, especially for high-risk patients.